ESSA Retained Earnings vs Capital Stock Analysis
| EPIX Stock | USD 6.20 0.04 0.64% |
ESSA Pharma financial indicator trend analysis is much more than just examining ESSA Pharma latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether ESSA Pharma is a good investment. Please check the relationship between ESSA Pharma Retained Earnings and its Capital Stock accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in ESSA Pharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy ESSA Stock please use our How to Invest in ESSA Pharma guide.
Retained Earnings vs Capital Stock
Retained Earnings vs Capital Stock Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of ESSA Pharma Retained Earnings account and Capital Stock. At this time, the significance of the direction appears to have pay attention.
The correlation between ESSA Pharma's Retained Earnings and Capital Stock is -0.94. Overlapping area represents the amount of variation of Retained Earnings that can explain the historical movement of Capital Stock in the same time period over historical financial statements of ESSA Pharma, assuming nothing else is changed. The correlation between historical values of ESSA Pharma's Retained Earnings and Capital Stock is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Retained Earnings of ESSA Pharma are associated (or correlated) with its Capital Stock. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capital Stock has no effect on the direction of Retained Earnings i.e., ESSA Pharma's Retained Earnings and Capital Stock go up and down completely randomly.
Correlation Coefficient | -0.94 |
| Relationship Direction | Negative |
| Relationship Strength | Significant |
Retained Earnings
The cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends.Capital Stock
The total amount of a company’s capital funded by shareholders through the issue and subscription of shares.Most indicators from ESSA Pharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into ESSA Pharma current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in ESSA Pharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy ESSA Stock please use our How to Invest in ESSA Pharma guide.Enterprise Value is likely to rise to about 97 M in 2024, whereas Selling General Administrative is likely to drop slightly above 7.6 M in 2024.
ESSA Pharma fundamental ratios Correlations
Click cells to compare fundamentals
ESSA Pharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
ESSA Pharma fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 80.6M | 198.2M | 169.5M | 149.1M | 171.5M | 180.1M | |
| Other Current Liab | 676.0 | 2.4M | 1.2M | 1.4M | 1.6M | 1.0M | |
| Total Current Liabilities | 1.2M | 3.9M | 2.3M | 3.5M | 4.0M | 3.3M | |
| Total Stockholder Equity | 79.2M | 194.0M | 167.1M | 145.6M | 167.5M | 175.8M | |
| Other Liab | 19.6K | 16.5K | 127.4K | 20.4K | 18.3K | 17.4K | |
| Net Tangible Assets | 49.0M | 79.2M | 194.0M | 167.1M | 192.2M | 201.8M | |
| Retained Earnings | (81.0M) | (117.8M) | (152.9M) | (179.5M) | (161.5M) | (153.4M) | |
| Accounts Payable | 1.1M | 1.4M | 954.6K | 2.0M | 2.3M | 1.6M | |
| Cash | 56.3M | 137.8M | 57.1M | 33.7M | 38.8M | 37.2M | |
| Other Assets | (55.2K) | 198.2M | (446.0K) | 115.4M | 132.7M | 139.3M | |
| Net Receivables | 309.5K | 489.0K | 6.2K | 135.1K | 121.6K | 115.5K | |
| Inventory | 420.5K | (360.8K) | (309.5K) | 110.6M | 127.2M | 133.6M | |
| Other Current Assets | 24.3M | 2.2M | 1.8M | 585.4K | 673.2K | 639.6K | |
| Other Stockholder Equity | 31.2M | 36.4M | 44.0M | 49.0M | 56.4M | 59.2M | |
| Total Liab | 1.3M | 4.2M | 2.4M | 3.5M | 3.1M | 3.6M | |
| Total Current Assets | 80.6M | 197.6M | 169.5M | 148.8M | 171.1M | 179.7M | |
| Short Term Debt | 59.1K | 120.7K | 133.8K | 80.3K | 92.4K | 87.8K | |
| Common Stock | 131.1M | 277.4M | 278.1M | 278.2M | 319.9M | 335.9M | |
| Net Debt | (56.3M) | (137.5M) | (56.9M) | (33.6M) | (30.3M) | (31.8M) | |
| Non Current Assets Total | 55.2K | 567.7K | 446.0K | 325.3K | 292.7K | 301.5K | |
| Cash And Short Term Investments | 56.3M | 194.9M | 57.1M | 148.1M | 170.3M | 178.8M | |
| Common Stock Shares Outstanding | 22.4M | 38.5M | 44.0M | 44.1M | 50.7M | 53.2M | |
| Liabilities And Stockholders Equity | 80.6M | 198.2M | 169.5M | 149.1M | 171.5M | 180.1M | |
| Non Currrent Assets Other | (200.7K) | 277.6K | 259.5K | 257.2K | 295.8K | 201.5K | |
| Short Long Term Debt Total | 59.1K | 331.0K | 209.8K | 80.3K | 72.3K | 68.7K | |
| Net Invested Capital | 79.2M | 194.0M | 167.1M | 145.6M | 167.5M | 103.4M | |
| Net Working Capital | 79.1M | 193.7M | 166.7M | 145.3M | 167.1M | 101.6M | |
| Capital Stock | 131.1M | 277.4M | 278.1M | 278.2M | 319.9M | 198.2M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether ESSA Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ESSA Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Essa Pharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Essa Pharma Stock:Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in ESSA Pharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy ESSA Stock please use our How to Invest in ESSA Pharma guide.You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Complementary Tools for ESSA Stock analysis
When running ESSA Pharma's price analysis, check to measure ESSA Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ESSA Pharma is operating at the current time. Most of ESSA Pharma's value examination focuses on studying past and present price action to predict the probability of ESSA Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ESSA Pharma's price. Additionally, you may evaluate how the addition of ESSA Pharma to your portfolios can decrease your overall portfolio volatility.
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities |
Is ESSA Pharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ESSA Pharma. If investors know ESSA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ESSA Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.63) | Return On Assets (0.14) | Return On Equity (0.19) |
The market value of ESSA Pharma is measured differently than its book value, which is the value of ESSA that is recorded on the company's balance sheet. Investors also form their own opinion of ESSA Pharma's value that differs from its market value or its book value, called intrinsic value, which is ESSA Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ESSA Pharma's market value can be influenced by many factors that don't directly affect ESSA Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ESSA Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if ESSA Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ESSA Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.